B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
Benzinga10 days agoDNLI
Denali Therapeutics: Bullish On Avlayah And Their Prospects
Denali Therapeutics' main improvement lies with AVLAYAH, moving it from a platform story into a commercial-stage biotech. See why DNLI stock is a buy.
SeekingAlpha16 days agoDNLI
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
SeekingAlpha17 days agoDNLI
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy.
SeekingAlpha22 days agoDNLI
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout
Denali Therapeutics (DNLI): perfect technical & setup scores. Uptrend with tight consolidation. Breakout above $25.84, stop below $23.01.
ChartMill23 days agoDNLI
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.
Benzinga28 days agoDNLI
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsLaura HansenRyan Watts - Co-Founder, President, CEO...
SeekingAlpha28 days agoDNLI
Denali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Denali Therapeutics Inc.
SeekingAlpha28 days agoDNLI
Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates
Denali Therapeutics (DNLI) stock fell 12% after Q2 revenue miss. AVLAYAH sales low, but Q3 guidance of $10-12M signals acceleration.
ChartMill29 days agoDNLI
Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of $(0.72) per share
Benzinga29 days agoDNLI